[Long-term survival analysis of 1 367 patients treated with radical nephrectomy from a single center]
- PMID: 37968085
- DOI: 10.3760/cma.j.cn112152-20220614-00420
[Long-term survival analysis of 1 367 patients treated with radical nephrectomy from a single center]
Abstract
Objective: To report the long-term survival of renal cell carcinoma (RCC) patients treated with radical nephrectomy in Sun Yat-sen University Cancer Center. Methods: We retrospectively analyzed the clinical, pathological and follow-up records of 1 367 non-metastatic RCC patients treated with radical nephrectomy from 1999 to 2020 in this center. The primary endpoint of this study was overall survival rate. Survival curves were estimated using the Kaplan-Meier method, and group differences were compared through Log-rank test. Univariate and multivariate Cox analysis were fit to determine the clinical and pathological features associated with overall survival rate. Results: A total of 1 367 patients treated with radical nephrectomy with complete follow-up data were included in the study. The median follow-up time was 52.6 months, and 1 100 patients survived and 267 died, with the median time to overall survival not yet reached. The 5-year and 10-year overall survival rates were 82.8% and 74.9%, respectively. The 5-year and 10-year overall survival rates of Leibovich low-risk patients were 93.3% and 88.2%, respectively; of Leibovich intermediate-risk patients were 82.2% and 72.3%, respectively; and of Leibovich high-risk patients were 50.5% and 30.2%, respectively. There were significant differences in the long-term survival among the three groups (P<0.001). The 10-year overall survival rates for patients with pT1, pT2, pT3 and pT4 RCC were 83.2%, 73.6%, 55.0% and 31.4%, respectively. There were significant differences among pT1, pT2, pT3 and pT4 patients(P<0.001). The 5-year and 10-year overall survival rates of patients with lymph node metastasis were 48.5% and 35.6%, respectively, and those of patients without lymph node metastasis were 85.1% and 77.5%, respectively. There was significant difference in the long-term survival between patients with lymph node metastasis and without lymph node metastasis. The 10-year overall survival rate was 96.2% for nuclear Grade 1, 81.6% for nuclear Grade 2, 60.5% for nuclear Grade 3, and 43.4% for nuclear Grade 4 patients. The difference was statistically significant. There was no significant difference in the long-term survival between patients with localized renal cancer (pT1-2N0M0) who underwent open surgery and minimally invasive surgery (10-year overall survival rate 80.5% vs 85.6%, P=0.160). Multivariate Cox analysis showed that age≥55 years (HR=2.11, 95% CI: 1.50-2.96, P<0.001), T stage(T3+ T4 vs T1a: HR=2.37, 95% CI: 1.26-4.46, P=0.008), local lymph node metastasis (HR=3.04, 95%CI: 1.81-5.09, P<0.001), nuclear grade (G3-G4 vs G1: HR=4.21, 95%CI: 1.51-11.75, P=0.006), tumor necrosis (HR=1.66, 95% CI: 1.17-2.37, P=0.005), sarcomatoid differentiation (HR=2.39, 95% CI: 1.31-4.35, P=0.005) and BMI≥24kg/m(2) (HR=0.56, 95%CI: 0.39-0.80, P=0.001) were independent factors affecting long-term survival after radical nephrectomy. Conclusions: The long-term survival of radical nephrectomy in patients with renal cell carcinoma is satisfactory. Advanced age, higher pathological stage and grade, tumor necrosis and sarcomatoid differentiation were the main adverse factors affecting the prognosis of patients. Higher body mass index was a protective factor for the prognosis of patients.
目的: 总结报道中山大学肿瘤防治中心肾癌患者根治性肾切除术后的远期生存情况。 方法: 收集1999—2020年在中山大学肿瘤防治中心接受根治性肾切除术的1 367例无远处转移肾癌患者的临床病理和随访资料,以总生存为主要研究终点,采用Kaplan-Meier法进行生存分析,组间生存率的比较采用Log rank检验。肾癌患者根治性肾切除术后总生存的影响因素分析采用单因素和多因素Cox比例风险模型回归分析。 结果: 中位随访52.6个月,1 367例患者中死亡267例,存活1 100例,中位总生存时间尚未达到,5年和10年总生存率分别为82.8%和74.9%。Leibovich评分低危组、中危组和高危组患者的5年总生存率分别为93.3%、82.2%和50.5%,10年总生存率分别为88.2%、72.3%和30.2%,3组远期生存差异有统计学意义(P<0.001)。pT1期、pT2期、pT3期和pT4期肾癌患者的10年总生存率分别为83.2%、73.6%、55.0%和31.4%,差异有统计学意义(P<0.001)。有淋巴结转移患者的5年和10年总生存率分别为48.5%和35.6%,无淋巴结转移患者的5年和10年总生存率分别为85.1%和77.5%,差异有统计学意义(P<0.001)。核分级G1级、G2级、G3级和G4级患者的10年总生存率分别为96.2%、81.6%、60.5%和43.4%,差异有统计学意义(P<0.001)。局限性肾癌(pT1~2N0M0)患者接受开放手术和微创手术后的10年总生存率分别为80.5%和85.6%,差异无统计学意义(P=0.160)。多因素Cox回归分析显示,性别、年龄、体质指数(BMI)、T分期、N分期、病理核分级、肿瘤坏死、肉瘤样分化是肾癌患者根治性肾切除术后总生存的独立影响因素,男性(HR=1.55,95% CI:1.04~2.31)、年龄≥55岁(HR=2.11,95% CI:1.50~2.96)、高T分期(T3~4期比T1a期:HR=2.37,95% CI:1.26~4.46)、N1期(HR=3.04,95% CI:1.81~5.09)、高病理核分级(G3~4比G1:HR=4.21,95%CI:1.51~11.75)、有肿瘤坏死(HR=1.66,95% CI:1.17~2.37)和有肉瘤样分化(HR=2.39,95% CI:1.31~4.36)的肾癌患者根治性肾切除术后总生存较差,BMI≥24 kg/m(2)的肾癌患者根治性肾切除术后总生存较好(HR=0.56,95% CI:0.39~0.80)。 结论: 肾癌患者行根治性肾切除后远期总生存率高。高龄、高病理分期和核分级、有肿瘤坏死和肉瘤样分化是肾癌患者根治性肾切除术后远期生存的主要不良影响因素,高BMI是主要的保护因素。.
Keywords: Radical nephrectomy; Renal neoplasms; Survival analysis.
Similar articles
-
[Clinicopathological features and prognostic analysis of papillary renal cell carcinoma].Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Aug 18;54(4):615-620. doi: 10.19723/j.issn.1671-167X.2022.04.006. Beijing Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 35950382 Free PMC article. Chinese.
-
[Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].Zhonghua Zhong Liu Za Zhi. 2023 Aug 23;45(8):681-689. doi: 10.3760/cma.j.cn112152-20221027-00722. Zhonghua Zhong Liu Za Zhi. 2023. PMID: 37580273 Chinese.
-
Retrospective Multicenter Analysis of Prognostic Risk Factors for One Year Recurrence in Patient With Renal Cell Carcinoma After Partial or Radical Nephrectomy: Results of Korean Renal Cancer Study Group (KRoCS) Database.J Korean Med Sci. 2024 Jan 22;39(3):e11. doi: 10.3346/jkms.2024.39.e11. J Korean Med Sci. 2024. PMID: 38258358 Free PMC article.
-
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.Urology. 2003 Oct;62(4):641-6. doi: 10.1016/s0090-4295(03)00489-8. Urology. 2003. PMID: 14550434 Review.
-
Lymph node dissection in renal cell carcinoma.Eur Urol. 2011 Dec;60(6):1212-20. doi: 10.1016/j.eururo.2011.09.003. Epub 2011 Sep 13. Eur Urol. 2011. PMID: 21940096 Review.
Cited by
-
Survival outcomes and risk factors for liver and pancreatic metastases in renal cell carcinoma after curative nephrectomy.BMC Urol. 2025 May 15;25(1):123. doi: 10.1186/s12894-025-01802-x. BMC Urol. 2025. PMID: 40369561 Free PMC article.
-
A predictive model for WHO/ISUP pathologic grading of renal clear cell carcinoma based on CT radiomics: a multicenter study.BMC Nephrol. 2025 Jul 1;26(1):296. doi: 10.1186/s12882-025-04268-z. BMC Nephrol. 2025. PMID: 40597030 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical